Anavex Life Sciences Corp (AVXL)

[Investor2014]

I think Missling may be saying that the current Rett trial is designed with a P3 in mind with regards to what the regulator will accept as endpoints for approval.

Missling may be saying that since Kaufmann is the recognised specialist in Rett and he is now the CMO of Anavex, the 'authoritative' measure to date is the RSBQ. Hence RSBQ also figures as the first of the secondary efficacy endpoints of the initial P2 safety trial, which moves up to be the primary endpoint in the P3.

And yes the Neuren P3 trial mesage from Acadia says: "The study will use the Rett Syndrome Behaviour Questionnaire (RSBQ)".

More speculation is that Anavex is skirting the juveniles both in the current P2 and in the following P3 to get A2-73 approved and take it from there.